Polyrizon Ltd. (PLRZ), Friday announced the successful completion of preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product's development path.
The study, conducted on fully differentiated human nasal tissue, assessed local tolerance and tissue response following a 4-hour application of a formulation of PL-14, a mucoadhesive nasal gel spray.
The findings revealed strong local tolerability, consistency in tissue viability and function, and zero signs of inflammatory activation or functional impairment of nasal epithelial activity.
The company noted that the encouraging data would serve as a key step in Polyrizon's regulatory strategy and will support its upcoming FDA pre-submission meeting, paving the way for U.S. and European clinical trials expected to begin in late 2025 or early 2026.
In the pre-market hours, Polyrizon's stock is trading at $0.31, down 10.74 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com